Latest news with #Boloor
Business Wire
5 days ago
- Business
- Business Wire
Futurum Group Launches Futurum Equities Research and Appoints Shay Boloor as Chief Market Strategist to Lead New Division
AUSTIN, Texas--(BUSINESS WIRE)--Futurum Group, a leader in technology-focused market intelligence, advisory and research, today announced the launch of its latest offering and division, Futurum Equities Research. The new arm will be led by newly-appointed Chief Market Strategist Shay Boloor, effective immediately. In this role, Boloor will spearhead the production of Futurum Equities' daily morning market notes, now distributed to over 7,000 recipients, on top of Futurum's clientele and subscribers. In addition, Boloor will run his daily show and new content on StockTwits, as well as partake in various Futurum media shows. Futurum Equities will introduce clients to its philosophy of 'A.I.R' − Access, Insights, Research, creating 'capital intelligence' to enable more informed decision making in trading. Share Shay Boloor, widely recognized by his online moniker @StockSavvyShay, brings a wealth of experience and a dynamic presence in the financial analysis community to nearly 200K direct followers. He is known for his insightful commentary on Stocktwits and his engaging co-hosting of " Daily Rip Live" alongside Katie Perry, as well as appearances in many business broadcast networks. "Shay's unique ability and energetic style to distill complex market dynamics into actionable insights has positioned him as a trusted voice among technology and retail investors," said Daniel Newman, CEO of Futurum. "His leadership and his insightful market analysis will be instrumental as we expand our offerings to meet the evolving needs of our audiences, clients and the broader investment community. With the rapidly changing research and media landscape, Futurum Equities exemplifies our pioneering DNA, which is rooted in continuous innovation to drive deeper engagement and enrich the clients and audience we serve." "I'm excited to lead Futurum Equities Research and bring real-time, actionable insights to the retail investment community,' said incoming Chief Market Strategist Shay Boloor. 'Retail investors now dominate the market but remain the most underserved. We're changing that -- delivering the A.I.R. retail investors need to succeed: Access, Insights, and Research. With Futurum's deep tech network, we're leveling the playing field and giving retail the edge institutions have long held." Futurum Equities Research will introduce clients to its philosophy of 'A.I.R' − Access, Insights, Research, creating 'capital intelligence' to enable more informed decision making in trading. For clients, media and subscribers, Futurum Equities will issue a daily market note distributed ahead of market open, Mondays through Fridays. To sign up to receive the daily market note, visit: To expand and continue its broad reach and distribution, Futurum Equities announced a unique collaboration with Stocktwits, a leading community for investors, traders and trading information. About Shay Boloor Incoming Futurum Equities Research Shay Boloor is a growth investor and market analyst focused on tech, quantum, AI, & the space economy. Creator of the Futurum Daily Signal, an original deep-dive content distributed to 180K+ followers on X with 50M+ monthly impressions. Shay's appearances can be found on various business networks such as Bloomberg, Schwab Networks, Fox Business and CNN, among others. About Futurum The Futurum Group is the fastest growing independent tech research, intelligence, media, and advisory firm. Its continued growth is driven by emerging technologies and innovation across its clientele of more than 415 global companies. Futurum has established its reputation as a leader in global research, intelligence and advisory, focused on analyzing emerging technologies and market trends across enterprise, AI, cloud, semiconductor and tech transformation landscapes. Futurum helps businesses, investors, and technology providers make informed strategic decisions through its market intelligence products, thought leadership content, analyst briefings, and multimedia programming.
Yahoo
5 days ago
- Business
- Yahoo
Futurum Group Launches Futurum Equities Research and Appoints Shay Boloor as Chief Market Strategist to Lead New Division
Broadening Futurum's offerings in research, intelligence and tech insights, the new division will focus on market-moving stocks and offer exclusive access to top trade takes, key movements and unique insights geared towards the retail investor Newly appointed Chief Market Strategist Shay Boloor brings a proven track record and high visibility profile as a growth investor, market strategist, and content creator with 50M+ monthly impressions. His popular show 'Daily Rip Live', broadcast before market open, features actionable trading tips, deep dives and real time updates Futurum Equities has formed a unique collaboration with Stocktwits, the largest community for investors, traders, and stock market information, to host and distribute its video content and shows AUSTIN, Texas, June 05, 2025--(BUSINESS WIRE)--Futurum Group, a leader in technology-focused market intelligence, advisory and research, today announced the launch of its latest offering and division, Futurum Equities Research. The new arm will be led by newly-appointed Chief Market Strategist Shay Boloor, effective immediately. In this role, Boloor will spearhead the production of Futurum Equities' daily morning market notes, now distributed to over 7,000 recipients, on top of Futurum's clientele and subscribers. In addition, Boloor will run his daily show and new content on StockTwits, as well as partake in various Futurum media shows. Shay Boloor, widely recognized by his online moniker @StockSavvyShay, brings a wealth of experience and a dynamic presence in the financial analysis community to nearly 200K direct followers. He is known for his insightful commentary on Stocktwits and his engaging co-hosting of "Daily Rip Live" alongside Katie Perry, as well as appearances in many business broadcast networks. "Shay's unique ability and energetic style to distill complex market dynamics into actionable insights has positioned him as a trusted voice among technology and retail investors," said Daniel Newman, CEO of Futurum. "His leadership and his insightful market analysis will be instrumental as we expand our offerings to meet the evolving needs of our audiences, clients and the broader investment community. With the rapidly changing research and media landscape, Futurum Equities exemplifies our pioneering DNA, which is rooted in continuous innovation to drive deeper engagement and enrich the clients and audience we serve." "I'm excited to lead Futurum Equities Research and bring real-time, actionable insights to the retail investment community," said incoming Chief Market Strategist Shay Boloor. "Retail investors now dominate the market but remain the most underserved. We're changing that -- delivering the A.I.R. retail investors need to succeed: Access, Insights, and Research. With Futurum's deep tech network, we're leveling the playing field and giving retail the edge institutions have long held." Futurum Equities Research will introduce clients to its philosophy of 'A.I.R' − Access, Insights, Research, creating 'capital intelligence' to enable more informed decision making in trading. For clients, media and subscribers, Futurum Equities will issue a daily market note distributed ahead of market open, Mondays through Fridays. To sign up to receive the daily market note, visit: To expand and continue its broad reach and distribution, Futurum Equities announced a unique collaboration with Stocktwits, a leading community for investors, traders and trading information. About Shay Boloor Incoming Futurum Equities Research Shay Boloor is a growth investor and market analyst focused on tech, quantum, AI, & the space economy. Creator of the Futurum Daily Signal, an original deep-dive content distributed to 180K+ followers on X with 50M+ monthly impressions. Shay's appearances can be found on various business networks such as Bloomberg, Schwab Networks, Fox Business and CNN, among others. About Futurum The Futurum Group is the fastest growing independent tech research, intelligence, media, and advisory firm. Its continued growth is driven by emerging technologies and innovation across its clientele of more than 415 global companies. Futurum has established its reputation as a leader in global research, intelligence and advisory, focused on analyzing emerging technologies and market trends across enterprise, AI, cloud, semiconductor and tech transformation landscapes. Futurum helps businesses, investors, and technology providers make informed strategic decisions through its market intelligence products, thought leadership content, analyst briefings, and multimedia programming. View source version on Contacts Nati Katznkatz@ Sign in to access your portfolio
Yahoo
20-05-2025
- Business
- Yahoo
Covalon Retains Financial and Strategic Advisor to Advise on Shareholder Value-Enhancing Opportunities
MISSISSAUGA, Ontario, May 20, 2025--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has engaged Origin Merchant Partners as its financial and strategic advisor to advise on a range of opportunities aimed at maximizing shareholder value and expanding the reach of its innovative medical technologies. With the assistance of its financial and strategic advisor, the Company is exploring a range of shareholder value-enhancing opportunities, including but not limited to: Joint ventures, strategic partnerships, and acquisitions; Mergers or mergers of equals; In-licensing and out-licensing of products and intellectual property; A listing on the NASDAQ stock exchange; Stock buybacks leveraging the Company's net cash balance of approximately $18 million; and Potential spinoffs of one or both of its primary business segments—Advanced Wound Care and Vascular Access & Surgical Consumables—into distinct, focused entities. "Our primary objectives are to accelerate the adoption of our products to benefit a larger patient population and to unlock the significant value we believe is inherent in our Company," said Amir Boloor, Executive Chair of Covalon. "We believe Covalon is undervalued — trading at a mid-single-digit Adjusted EBITDA multiple compared to med-tech peers in Canada and the U.S., which typically trade at significantly higher multiples. This is despite the fact that we are making long-term investments and are not focused on near-term EBITDA optimization." Mr. Boloor also stated that "the Company's Advanced Wound Care segment, led by its collagen dressings, has grown more than 4x in the U.S. market over the past four years and contributed more than $10 million in Adjusted EBITDA on a standalone basis in our most recent fiscal year. We believe that we still have runway to improve margins and profitability and to grow this business over a multi-year time horizon through market share expansion and the launch of new products." "Our Vascular Access and Surgical Consumables segment—representing a smaller, but growing portion of our overall revenue today—has grown at a compound annual rate of over 50% in the U.S. market over the past three fiscal years, attracting some of the largest and most prestigious hospitals in the United States. This growth reflects the strong clinical value and differentiation of our products." There is no assurance that the exploration of these opportunities will result in any specific transaction or outcome. Covalon will not provide any further updates on this process unless and until it determines that further disclosure is required or appropriate. Non-GAAP Financial MeasuresThis press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards, and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures such as "Adjusted EBITDA" to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts, and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below: Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), accounts receivable write-offs, gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment. EBITDA as earnings before interest, taxes, depreciation, and amortization. You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to, some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definition of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing its utility. Net income (loss) is the most directly comparable GAAP financial measure to EBITDA. EBITDA is useful in assessing the performance of a company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. About CovalonCovalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking InformationThis news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. View source version on Contacts To learn more about Covalon, please contact:Investor Relations, Covalon Technologies investors@ Website: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20-05-2025
- Business
- Business Wire
Covalon Retains Financial and Strategic Advisor to Advise on Shareholder Value-Enhancing Opportunities
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has engaged Origin Merchant Partners as its financial and strategic advisor to advise on a range of opportunities aimed at maximizing shareholder value and expanding the reach of its innovative medical technologies. With the assistance of its financial and strategic advisor, the Company is exploring a range of shareholder value-enhancing opportunities, including but not limited to: Joint ventures, strategic partnerships, and acquisitions; Mergers or mergers of equals; In-licensing and out-licensing of products and intellectual property; A listing on the NASDAQ stock exchange; Stock buybacks leveraging the Company's net cash balance of approximately $18 million; and Potential spinoffs of one or both of its primary business segments—Advanced Wound Care and Vascular Access & Surgical Consumables—into distinct, focused entities. 'Our primary objectives are to accelerate the adoption of our products to benefit a larger patient population and to unlock the significant value we believe is inherent in our Company,' said Amir Boloor, Executive Chair of Covalon. 'We believe Covalon is undervalued — trading at a mid-single-digit Adjusted EBITDA multiple compared to med-tech peers in Canada and the U.S., which typically trade at significantly higher multiples. This is despite the fact that we are making long-term investments and are not focused on near-term EBITDA optimization.' Mr. Boloor also stated that 'the Company's Advanced Wound Care segment, led by its collagen dressings, has grown more than 4x in the U.S. market over the past four years and contributed more than $10 million in Adjusted EBITDA on a standalone basis in our most recent fiscal year. We believe that we still have runway to improve margins and profitability and to grow this business over a multi-year time horizon through market share expansion and the launch of new products.' 'Our Vascular Access and Surgical Consumables segment—representing a smaller, but growing portion of our overall revenue today—has grown at a compound annual rate of over 50% in the U.S. market over the past three fiscal years, attracting some of the largest and most prestigious hospitals in the United States. This growth reflects the strong clinical value and differentiation of our products.' There is no assurance that the exploration of these opportunities will result in any specific transaction or outcome. Covalon will not provide any further updates on this process unless and until it determines that further disclosure is required or appropriate. Non-GAAP Financial Measures This press release makes reference to certain non-GAAP measures. These measures are not recognized or defined measures under IFRS Accounting Standards, do not have standardized meaning prescribed by IFRS Accounting Standards, and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional financial information to complement those IFRS Accounting Standards measures by providing further understanding of our results of operations from management's perspective. Accordingly, these measures should not be considered in isolation or as a substitute for analysis of our financial information reported under IFRS Accounting Standards. The non-GAAP financial measures, adjustments, and reasons for adjustments should be carefully evaluated as these measures have limitations as analytical tools and should not be used in substitution for an analysis of the Company's results under IFRS Accounting Standards. We use non-GAAP measures such as 'Adjusted EBITDA' to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS Accounting Standards measures. We believe that securities analysts, investors, and other interested parties frequently use non-GAAP measures in the evaluation of issuers. Our management also uses non-GAAP measures in order to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and forecasts, and to determine components of management compensation. The following non-GAAP financial measures are presented in this news release, and a description of the calculation for each measure is included below: Adjusted EBITDA as earnings (loss) before interest expense (income), depreciation and amortization, stock-based compensation, inventory provisions (reversals), accounts receivable write-offs, gain (loss) on finance lease receivable, and loss (gain) on disposal of property and equipment. EBITDA as earnings before interest, taxes, depreciation, and amortization. You should also be aware that the Company may recognize income or incur expenses in the future that are the same as, or similar to, some of the adjustments in these non-GAAP financial measures. Because these non-GAAP financial measures may be defined differently by other companies in our industry, our definition of these non-GAAP financial measures may not be comparable to similarly titled measures of other companies, thereby diminishing its utility. Net income (loss) is the most directly comparable GAAP financial measure to EBITDA. EBITDA is useful in assessing the performance of a company's ongoing operations and its ability to generate cash flows to fund its cash requirements from period to period. About Covalon Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.
